Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | ERN1 | O75460 | 4/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10089356 | 0.86 | BCHE (0.40) | CYP2A6ERN1PTGS1PTGS2TP53 | |
| SCHEMBL10089369 | 0.79 | EGFR (0.39) | ALDH1A1HPGDMAOB | |
| SCHEMBL10089354 | 0.75 | CYP1A2 (0.36) | TP53SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL10089345 | 0.71 | HSD11B1 (0.40) | RXFP1ALDH1A1HPGDMAPT | |
| SCHEMBL10089384 | 0.68 | MAPT (0.38) | TP53ALDH1A1HPGDMAPT | |
| SCHEMBL12445306 | 0.68 | DHFR (0.35) | ALDH1A1HPGDMAOB | |
| SCHEMBL23088942 | 0.67 | ALDH1A1 (0.41) | CYP2A6ERN1PTGS1PTGS2APP | |
| SCHEMBL4381193 | 0.66 | CYP2A6 (0.54) | CYP2A6ERN1APPALDH1A1HPGD | |
| SCHEMBL2824135 | 0.66 | CYP2A6 (0.63) | CYP2A6ERN1APPSMN1; SMN2ALDH1A1 | |
| SCHEMBL15912542 | 0.66 | HSP90AA1 (0.48) | SMN1; SMN2ALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383753-B2 | Polydentate heteroatom ligand containing metal complexes, catalysts and methods of making and using the same | DOW GLOBAL TECHNOLOGIES, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383753-B2 | Polydentate heteroatom ligand containing metal complexes, catalysts and methods of making and using the same | DOW GLOBAL TECHNOLOGIES, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120029159-A1 | POLYDENTATE HETEROATOM LIGAND CONTAINING METAL COMPLEXES, CATALYSTS AND METHODS OF MAKING AND USING THE SAME | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120029159-A1 | POLYDENTATE HETEROATOM LIGAND CONTAINING METAL COMPLEXES, CATALYSTS AND METHODS OF MAKING AND USING THE SAME | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-02-02 | — | — | US | disclosed |
| US-8071701-B2 | Polydentate heteroatom ligand containing metal complexes, catalysts and methods of making and using the same | DOW GLOBAL TECHNOLOGIES LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071701-B2 | Polydentate heteroatom ligand containing metal complexes, catalysts and methods of making and using the same | DOW GLOBAL TECHNOLOGIES LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090221770-A1 | POLYDENTATE HETEROATOM LIGAND CONTAINING METAL COMPLEXES, CATALYSTS AND METHODS OF MAKING AND USING THE SAME | DOW GLOBAL TECHNOLOGIES INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221770-A1 | POLYDENTATE HETEROATOM LIGAND CONTAINING METAL COMPLEXES, CATALYSTS AND METHODS OF MAKING AND USING THE SAME | DOW GLOBAL TECHNOLOGIES INC. | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221770-A1 | POLYDENTATE HETEROATOM LIGAND CONTAINING METAL COMPLEXES, CATALYSTS AND METHODS OF MAKING AND USING THE SAME | PICALM, PARG, POLM | CYP2A6 3684/4885ERN1 3919/4885PTGS1 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.